Marinomed develops treatments specifically for anti-viral and immunological conditions.
Marinomed has used its discovery capabilities in the evolution of MAVIREX, a technology platform for the development of therapies that target more than 200 different respiratory virus strains based on polymers derived from red seaweed. Safety and efficacy of the MAVIREX technology platform have already been proven in clinical trials in adults and children.
The Company also develops a novel treatment against Type I allergy and autoimmune diseases. MAM-06.301 is an anti-allergy compound that has been shown to have an excellent safety and efficacy profile in pre-clinical development.
Marinomed has an additional pipeline of discovery-stage programs for immune-based disorders and infectious diseases.